Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMG-7289 |
Synonyms | |
Therapy Description |
IMG-7289 irreversibly inhibits lysine-specific demethylase 1 (KDM1A, LSD1), resulting in growth inhibition of hematopoietic cells (PMID: 29453291, PMID: 31801559). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMG-7289 | IMG7289|IMG 7289|Bomedemstat | KDM1A Inhibitor 15 | IMG-7289 irreversibly inhibits lysine-specific demethylase 1 (KDM1A, LSD1), resulting in growth inhibition of hematopoietic cells (PMID: 29453291, PMID: 31801559). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | myeloproliferative neoplasm | sensitive | IMG-7289 | Preclinical | Actionable | In a preclinical study, IMG-7289 treatment led to decreased JAK2 V617F allele burden in peripheral blood cells and splenic cells, decreased spleen size, and improved survival in a transgenic mouse model of myeloproliferative neoplasm expressing JAK2 V617F (PMID: 31723778). | 31723778 |
JAK2 V617F TP53 R248W | acute myeloid leukemia | predicted - sensitive | IMG-7289 | Preclinical - Cell culture | Actionable | In a preclinical study, IMG-7289 treatment led to inhibition of colony formation, increased apoptosis and induction of cell cycle arrest in an acute myeloid leukemia cell line harboring JAK2 V617F and TP53 R248W in culture (PMID: 31723778). | 31723778 |
JAK2 V617F | hematologic cancer | predicted - sensitive | IMG-7289 | Preclinical - Cell culture | Actionable | In a preclinical study, IMG-7289 treatment led to increased apoptosis induction in transformed cells expressing JAK2 V617F compared to cells expressing wild-type Jak2 in culture (PMID: 31723778). | 31723778 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06351631 | Phase III | IMG-7289 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | Recruiting | USA | NZL | ITA | GBR | AUS | 1 |
NCT04262141 | Phase II | IMG-7289 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | Active, not recruiting | USA | 0 |
NCT03136185 | Phase II | IMG-7289 | IMG-7289 in Patients With Myelofibrosis | Completed | USA | ITA | GBR | DEU | AUS | 0 |
NCT05223920 | Phase II | IMG-7289 | Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms | Completed | USA | NZL | ITA | GBR | DEU | AUS | 1 |
NCT05558696 | Phase II | IMG-7289 | Bomedemstat in Patients With Polycythemia Vera | Active, not recruiting | USA | GBR | AUS | 0 |